After firing several employees, FDA is planning to hire contractors in place of fired staff. The departed staffers include ...

Video Back Videos home Signature collection Essentials collection Artificial Intelligence ...

Medtronic (NYSE:MDT) announced that the FDA approved its Simplera Sync continuous glucose monitor for use with the.

EBR designed its WiSE system to significantly expand the population of patients who could benefit from CRT. The leadless ...

Several studies reported reduced itch severity and urticaria activity with dupilumab. The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria ...

At 3 years, Opdivo plus Yervoy led to an overall survival rate of 38% in patients with unresectable or metastatic hepatocellular carcinoma, compared to 24% with lenvatinib or sorafenib monotherapy.

Two former FDA leaders look at Commissioner Marty Makary’s early stumbles — and lay out a list of priorities to protect both ...

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and adolescents over 12 years of age in over a decade. The FDA has approved Regeneron’s ...

The U.S. has not seen the approval of a new sunscreen ingredient since the 1990s. The FDA’s plan to phase out animal testing removes one of the obstacles standing between Americans and new ...

Dupilumab is now approved for CSU patients aged 12+ not controlled by H1 antihistamines, targeting IL-4 and IL-13 pathways. Phase 3 trials showed significant reductions in itch and urticaria ...